Human Immunology Biosciences Raises $120M in Funding
Summary
Human Immunology Biosciences (HI-Bio™), a South San Francisco, CA-based clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), launched with $120m in financing. Led by Travis Murdoch, M.D., CEO, Human Immunology Biosciences is a clinical-stage biotechnology company focused on discovering and developing precision medicines for people suffering from immune-mediated diseases (IMDs). Felzartamab targets a protein expressed on the surface of mature plasma cells whose dysfunction is thought to drive several IMDs. Terms included a 15 percent equity stake in HI-Bio, milestone payments and single-to low-double-digit royalties on net sales. • Mark Murcko, Ph.D., Founding Chief Scientific Officer at Dewpoint Therapeutics and Relay Therapeutics; and The company’s Scientific Advisory Board includes Mark Daly, Ph.D., Founding Chief of the Analytic and Translational Genetics Unit at Massachusetts General Hospital; John Davis, M.D., M.P.H., M.S., former Senior Vice President, Head of Early Clinical Development at Pfizer; Chris Goodnow, Ph.D., Executive Director of the Garvan Institute of Medical Research; Stefan Härtle, Ph.D., Head of Clinical Pharmacology at MorphoSys; Kristin Hogquist, Ph.D., Associate Director of the Center for Immunology at the University of Minnesota; Brian Kotzin, M.D., Senior Vice President, Clinical Development and Head of Immunology at Nektar Therapeutics; John Lowe, M.D., former Senior Director of Pathology at Genentech; Andrew Luster, M.D., Ph.D., Chief of the Division of Rheumatology, Allergy and Immunology at Massachusetts General Hospital; and Gregg Silverman, M.D., Mamdouha S. Bobst Professor of Internal Medicine, Department of Medicine at NYU Langone Health.